NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- CD16/IL15/CD33 trispecific killer cell engager
A trispecific killer engager (TriKE) molecule containing an anti-cluster of differentiation 16 (CD16; FcgammaRIII) single-chain variable fragment (scFv) to engage natural killer (NK) cells, an anti-CD33 scFv to engage myeloid cells and a human modified interleukin-15 (IL-15) linker, that links the two scFv, with potential immunomodulating and antineoplastic activities against CD33-expressing tumor cells. Upon administration of the CD16/IL15/CD33 TriKE, the simultaneous binding to CD16 on NK cells and CD33 on tumor cells will induce NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine IL-15 linker promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: CD16/IL-15/CD33 161533 tri-specific killer engagers
Code name: 161533